Press Releases Veru Inc.

Equities

VERU

US92536C1036

Real-time Estimate Cboe BZX Other stock markets 02:31:15 2024-05-07 pm EDT			5-day change	1st Jan Change
1.655 ^USD	+0.91%		+22.59%	+129.86%

May. 06	HC Wainwright Adjusts Veru Price Target to $3 From $2, Maintains Buy Rating	MT
Apr. 30	Veru Inc. Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Veru to Present at the GLP-1 Based Therapeutics Summit	May. 02	AQ
Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024	May. 01	AQ
Veru : Corporate Presentation, May 2024	Apr. 30	PU
Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss	Apr. 30	AQ
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11	Apr. 25	AQ
Veru Announces Date of 2024 Annual Meeting of Shareholders	Apr. 01	AQ
Veru Reschedules Annual Meeting of Shareholders	Mar. 25	AQ
Veru Reschedules Annual Meeting of Shareholders	Mar. 22	AQ
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss	Mar. 12	AQ
Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q	Feb. 27	AQ
Healthcare Innovations and Collaborations Fuel Industry Expansion Stocks Under $1 Look Now! OCGN, VTAK, RSCI, VERU, AGEN	Feb. 21	AQ
Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss	Feb. 20	AQ
Veru Reports Fiscal 2024 First Quarter Financial Highlights	Feb. 08	AQ
Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs	Feb. 06	AQ
Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	Jan. 31	AQ
Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024	Jan. 25	AQ
Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss	Jan. 08	AQ
Veru to Host Investor Call on January 4th, 2024 to Discuss Recent Financing and Strategy to Prioritize the Development of Enobosarm as a Combination Treatment to Prevent Muscle Loss and Augment Fat Loss Associated with Weight Loss GLP-1 Drugs	Dec. 19	AQ
VERU ALERT: Bragar Eagel & Squire, P.C. is Investigating Veru Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm	Dec. 14	BU
Veru Announces Pricing of Public Offering of Common Stock	Dec. 14	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Veru Inc.

Equities

VERU

US92536C1036

Press Releases

Filters